At a glance
ClinicalIndex Comparison RecordPhase 3Completed· 318 enrolled
Drug / intervention
Reproxalap Ophthalmic Solution (0.25%) +2 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Phase 3 Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions (0.25% and 0.5%) Compared to Vehicle in the Conjunctival Allergen Challenge (Ora-CAC®) Model of Acute Allergic Conjunctivitis
In Brief
A Phase 3 clinical trial evaluating Reproxalap Ophthalmic Solution (0.25%), Reproxalap Ophthalmic Solution (0.5%), and 1 other intervention for Allergic Conjunctivitis. Completed, enrolled 318 participants across 7 sites.
Detailed Summary
A Multi-Center, Double-Masked, Randomized, Parallel-Group, Vehicle-Controlled, Clinical Trial to Assess the Safety and Efficacy of Reproxalap Ophthalmic Solutions in Subjects with Acute Allergic Conjunctivitis
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsAllergic Conjunctivitis
CountriesUnited States
Collaborators--
Timeline
Phase 3CompletedFinished
20192020202120222023202420252026
Enrollment StartMar 2018
First PostedApr 2018
Primary CompletionNov 2018
TodayJul 2026
First PostedApr 11, 2018
Enrollment StartMar 30, 2018
Primary CompletionNov 5, 2018
TodayJul 2, 2026
Enrollment to primary: 7 monthsPosted 8.2 years ago
Interventions
Reproxalap Ophthalmic Solution (0.25%)drug
Reproxalap Ophthalmic Solution (0.25%) administered once.
Reproxalap Ophthalmic Solution (0.5%)drug
Reproxalap Ophthalmic Solution (0.5%) administered once.
Vehicle Ophthalmic Solutiondrug
Vehicle Ophthalmic Solution administered once.